AI & Emerging Technology

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.

Pluristyx secures a key Japanese patent for its rapid mRNA reprogramming tech, slashing iPSC production time and promising to unlock commercial-scale cell therapy.

Pasithea Therapeutics is expanding its NF1 trial for PAS-004, a move that signals a deeper strategic commitment to outmaneuvering competitors and meeting a critical unmet medical need.

As Latus Bio advances its Huntington's therapy to clinic, new CBO Bethany Mancilla brings a history of high-value deals to fuel the company's growth.

A new partnership between Peak Nano and Advanced Conversion solves a key thermal challenge in high-voltage EVs, strengthening the US supply chain.

A top German automaker is testing Teradar's new terahertz sensor, a technology that promises lidar-like clarity in any weather, to solve autonomy's biggest flaw.

Sweeping the London Design Awards is more than a PR victory for NAVEE. It’s a calculated move in a larger strategy to dominate intelligent outdoor mobility.

Roblox touted age verification as a key growth driver. Now, a lawsuit alleges it misled investors as the feature choked user growth and tanked the stock.

A new grant program aims to break the world's reliance on risky mineral supply chains by funding breakthrough research from seawater lithium to novel solar tech.

Havila Kystruten's record 87% occupancy and soaring revenues defy market uncertainty, showcasing how a modern fleet and shrewd strategy are rewriting the rules.

A new global study reveals a clear public mandate: deploy robots for heavy lifting, not for human connection. But a generational shift is already underway.

By poaching top analysts from WARC and MAGNA, Brian Wieser's consultancy is making a bold play to dominate the global advertising intelligence market.

Univest Securities secures $8M for Pop Culture Group via a direct offering. We look under the hood at the deal's mechanics and CPOP's ambitious growth plans.

As the Texas Center for Legal Ethics appoints seasoned veterans, it's more than a shuffle. It’s a strategic move to tackle AI, access to justice, and more.

A new clinical trial, backed by the Michael J. Fox Foundation, tests a radical idea: an oral drug derived from carbon monoxide to fight Parkinson's.

As AI promises to revolutionize medicine, enterprises face complex challenges. A new ISG study aims to chart the critical partner ecosystem.

Immuta's expanded Databricks partnership introduces a new security paradigm for autonomous AI, promising to turn a critical risk into a commercial advantage.

Restore Hyper Wellness is using a gamified challenge to keep clients engaged this summer. But is this a new frontier in personal resilience or just savvy marketing?

Novarc's Physical AI is joining forces with Yaskawa's robotic muscle, promising to bring true autonomy and intelligence to the factory floor. Here's why.

A seasoned investment team leaves the world of institutional giants to bring their emerging market strategy to the public through two new actively managed ETFs.